Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral satraplatin in this patient population.
Epistemonikos ID: becda172e7ee2a44ab6d73286a642e81e4691c13
First added on: May 04, 2024